Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, 1425 Madison Avenue Room 14-34, New York, NY 10029, USA.
Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA.
J Inherit Metab Dis. 2019 Jan;42(1):186-194. doi: 10.1002/jimd.12040.
Acute intermittent porphyria (AIP), an autosomal dominant disorder due to the half-normal activity of hydroxymethylbilane synthase (HMBS), is characterized by acute neurovisceral attacks that are precipitated by factors that induce heme biosynthesis. Molecular diagnosis is the most sensitive and specific diagnostic test for AIP, and importantly, it permits the identification of asymptomatic family members for genetic counseling and avoidance of precipitating factors. Here, we report the identification of 40 novel HMBS mutations, including 11 missense, four nonsense, 16 small insertions or deletions, eight consensus splice site mutations, and a complex insertion-deletion mutation in unrelated individuals with AIP. Prokaryotic expression of the missense mutations demonstrated that all mutants had ≤5% of expressed wildtype activity, except for c.1039G>C (p.A347P), which had 51% residual HMBS activity but was markedly thermolabile. Of note, the mutation c.612G>T (p.Q204H) altered the last nucleotide of exon 10, which resulted in an alternative HMBS transcript with an in-frame nine base-pair deletion at the 3'-terminus of exon 10 (encoding protein Q204HΔ3). When expressed, Q204HΔ3 and an in-frame three base-pair deletion (c.639_641delTGC) had no detectable HMBS activity. Western blot analyses and mapping of the missense mutations on the human HMBS crystal structure revealed that mutations near the active site or at the dimerization interface resulted in stably expressed proteins, while most that altered surface residues resulted in unstable proteins, presumably due to improper protein folding. These studies identified novel pathogenic HMBS mutations and expanded the molecular heterogeneity of AIP.
急性间歇性血卟啉病(AIP)是一种常染色体显性遗传病,由于羟甲基胆素合酶(HMBS)的活性减半,其特征是急性神经内脏发作,由诱导血红素生物合成的因素引发。分子诊断是 AIP 最敏感和特异的诊断试验,重要的是,它允许识别无症状的家族成员进行遗传咨询和避免诱发因素。在这里,我们报告了 40 种新的 HMBS 突变的鉴定,包括 11 种错义突变、4 种无义突变、16 种小插入或缺失、8 种共识剪接位点突变以及在无关联的 AIP 个体中一种复杂的插入缺失突变。错义突变的原核表达表明,除 c.1039G>C(p.A347P)外,所有突变体的表达野生型活性均≤5%,而 c.1039G>C(p.A347P)则具有 51%的残余 HMBS 活性,但明显热不稳定。值得注意的是,突变 c.612G>T(p.Q204H)改变了第 10 外显子的最后一个核苷酸,导致第 10 外显子 3'末端有一个框内 9 个碱基对缺失的 HMBS 转录本(编码蛋白 Q204HΔ3)。当表达时,Q204HΔ3 和框内三碱基对缺失(c.639_641delTGC)没有检测到 HMBS 活性。Western blot 分析和错义突变在人 HMBS 晶体结构上的定位表明,靠近活性位点或二聚化界面的突变导致稳定表达的蛋白质,而大多数改变表面残基的突变导致不稳定的蛋白质,可能是由于蛋白质折叠不当。这些研究鉴定了新的致病性 HMBS 突变,并扩展了 AIP 的分子异质性。